The role of the enzyme-modified comet assay in in vivo studies.

8-Oxoguanine DNA glycosylase Comet assay Endonuclease III Enzyme-modified comet assay Formamidopyrimidine DNA glycosylase In vivo

Journal

Toxicology letters
ISSN: 1879-3169
Titre abrégé: Toxicol Lett
Pays: Netherlands
ID NLM: 7709027

Informations de publication

Date de publication:
01 Jul 2020
Historique:
received: 03 01 2020
revised: 18 03 2020
accepted: 20 03 2020
pubmed: 6 4 2020
medline: 13 6 2020
entrez: 6 4 2020
Statut: ppublish

Résumé

The in vivo comet assay is an established genotoxicity test, with an OECD test guideline, but in its standard form it measures only DNA strand breaks. Including in the assay an additional step, in which the DNA is incubated with a lesion-specific enzyme, can provide important information about the nature of the DNA damage. Formamidopyrimidine DNA glycosylase, 8-oxoguanine DNA glycosylase or endonuclease III are commonly used in the in vitro genotoxicity test and in human biomonitoring to detect oxidised bases, but in vivo applications are rarer. A systematic literature search has identified a total of 60 papers that report such in vivo experiments, testing a variety of agents. In many cases, strand breaks were not seen, but significant levels of enzyme-sensitive sites were induced - indicating a mechanism of action involving oxidative stress. Compounds such as methyl methanesulfonate (MMS) or ethyl methanesulfonate (EMS) could be used as positive controls in both the standard and the enzyme-modified in vivo comet assays.

Identifiants

pubmed: 32247831
pii: S0378-4274(20)30096-5
doi: 10.1016/j.toxlet.2020.03.016
pii:
doi:

Substances chimiques

DNA 9007-49-2

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

58-68

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Andrew Collins (A)

Department of Nutrition, Institute for Basic Medical Sciences, University of Oslo, Sognsvannsveien 9, 0372, Oslo, Norway.

Ariane Vettorazzi (A)

Department of Pharmacology and Toxicology, University of Navarra, C/Irunlarrea 1, 31009, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Spain.

Amaya Azqueta (A)

Department of Pharmacology and Toxicology, University of Navarra, C/Irunlarrea 1, 31009, Pamplona, Spain. Electronic address: amazqueta@unav.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH